Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18778172 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | July 2024 | September 2024 | Allow | 2 | 0 | 0 | No | No |
| 18634865 | 1-(NAPHTHALEN-2-YLOXY)-3-(PIPERIDIN-1-YL)PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | April 2024 | September 2024 | Allow | 5 | 1 | 0 | No | No |
| 18605319 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | March 2024 | March 2026 | Abandon | 24 | 0 | 1 | No | No |
| 18428316 | CD73 COMPOUNDS | January 2024 | July 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18427164 | RAD51 INHIBITORS | January 2024 | May 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18425970 | 2-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 2 | 0 | No | No |
| 18425961 | 2-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18417867 | N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 8 | 0 | 0 | No | No |
| 18405058 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | January 2024 | January 2025 | Allow | 13 | 1 | 1 | No | No |
| 18393818 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | December 2023 | October 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18540695 | Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency | December 2023 | March 2026 | Allow | 27 | 0 | 0 | No | No |
| 18529485 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | December 2023 | September 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18561374 | METHODS OF SYNTHESIS OF HETEROARYL DERIVATIVES OF TRIAZOLYL ACRYLAMIDES AND CRYSTALLINE FORMS | November 2023 | March 2026 | Allow | 28 | 0 | 0 | No | No |
| 18561308 | RIP1 MODULATORS INCLUDING AZETIDINE CYCLIC UREAS, PREPARATIONS, AND USES THEREOF | November 2023 | March 2026 | Allow | 28 | 0 | 0 | No | No |
| 18388765 | Benzimidazoles and Methods of Using Same | November 2023 | November 2024 | Allow | 12 | 1 | 0 | No | No |
| 18504672 | DEUTERATED COMPOUNDS AND USES THEREOF | November 2023 | November 2024 | Allow | 12 | 1 | 1 | No | No |
| 18497891 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | October 2023 | July 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18491021 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | October 2023 | November 2024 | Allow | 13 | 1 | 0 | No | No |
| 18556243 | SOLID STATE FORMS OF (S)-N-(3-(2-(((R)-1-HYDROXYPROPAN-2-YL)AMINO)-6-MORPHOLINOPYRIDIN-4-YL)-4-METHYLPHENYL)-3-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SALTS THEREOF | October 2023 | March 2026 | Allow | 29 | 0 | 0 | No | No |
| 18482475 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | October 2023 | January 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18374282 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | September 2023 | September 2025 | Allow | 23 | 2 | 0 | No | No |
| 18477050 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | September 2023 | January 2025 | Allow | 16 | 1 | 0 | No | No |
| 18552679 | SYNTHESIS OF FLUORINATED CYCLIC DINUCLEOTIDES | September 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18373702 | COMPOUNDS AND USES THEREOF | September 2023 | November 2024 | Allow | 14 | 1 | 0 | No | No |
| 18476249 | FUSED PYRROLINES WHICH ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS | September 2023 | December 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18372417 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | September 2023 | March 2024 | Allow | 5 | 1 | 1 | No | No |
| 18464646 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | September 2023 | January 2025 | Allow | 16 | 2 | 0 | No | No |
| 18463707 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FGFR3-RELATED CHONDRODYSPLASIAS | September 2023 | November 2024 | Allow | 14 | 1 | 0 | No | No |
| 18463878 | PHOSPHINE REAGENTS FOR AZINE FLUOROALKYLATION | September 2023 | February 2025 | Abandon | 17 | 1 | 1 | No | No |
| 18549188 | THIOPHENE COMPOUND AND APPLICATION THEREOF | September 2023 | February 2026 | Allow | 29 | 0 | 0 | No | No |
| 18548739 | 4-ALKOXY-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 | September 2023 | March 2026 | Allow | 30 | 0 | 0 | No | No |
| 18546943 | TYK2 INHIBITORS AND USES THEREOF | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18546279 | TOPICAL COMPOSITIONS OPTIMISED FOR EPIDERMAL LIPIDS AND PHOSPHATIDYL GYCEROL | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18448277 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | August 2023 | November 2024 | Allow | 16 | 1 | 0 | No | No |
| 18275496 | HDAC6 INHIBITORS AND USES THEREOF | August 2023 | February 2026 | Allow | 30 | 0 | 0 | No | No |
| 18363661 | Processes for Preparing a MDM2 Inhibitor | August 2023 | September 2025 | Allow | 25 | 1 | 1 | No | No |
| 18361558 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | July 2023 | November 2024 | Allow | 16 | 0 | 1 | No | No |
| 18272820 | METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE | July 2023 | March 2026 | Allow | 32 | 1 | 0 | No | No |
| 18222688 | TETRACYCLIC COMPOUNDS AS DGK INHIBITORS | July 2023 | September 2025 | Allow | 26 | 0 | 0 | No | No |
| 18272439 | TRYPTAMINE ANALOGUES | July 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18272465 | COMPOSITION COMPRISING (7S)-(+)-CYCLOPENTYL CARBARMIC ACID, 8,8-DIMETHYL-2-OXO-6,7-DIHYDRO-2H,8H-PYRANO[3,2-G]CHROMEN-7-YL-ESTER AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF EYE DISEASE | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18261363 | METHOD FOR PURIFYING KEY INTERMEDIATES OF CITALOPRAM | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18221353 | FORMULATION OF METAXALONE | July 2023 | December 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18350152 | THIOUREYLENE LIQUID COMPOSITIONS | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18260703 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18348114 | METHODS OF INHIBITING KINASES | July 2023 | October 2024 | Allow | 15 | 1 | 0 | No | No |
| 18271162 | PYRIDONE MULTIPLE-MEMBERED RING DERIVATIVES AND USE THEREOF | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18344169 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18341950 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18342064 | FLUORESCENT DYES CONTAINING FUSED TETRACYCLIC BIS-BORON HETEROCYCLE AND USES IN SEQUENCING | June 2023 | October 2025 | Allow | 28 | 0 | 0 | No | No |
| 18259365 | NEW BISPHENOLS BEARING PENDANT CLICKABLE NORBORNENYL GROUP AND POLYMERS THEREFROM | June 2023 | March 2026 | Allow | 32 | 0 | 1 | No | No |
| 18337299 | TREATMENT OF CATAPLEXY | June 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18210306 | EIF4E INHIBITORS AND USES THEREOF | June 2023 | February 2024 | Allow | 8 | 0 | 0 | No | No |
| 18267177 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18257133 | PREPARATION OF TETRAHYDROINDAZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | June 2023 | September 2025 | Allow | 28 | 0 | 0 | No | No |
| 18330978 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | June 2023 | September 2025 | Abandon | 27 | 1 | 2 | No | No |
| 18202812 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | May 2023 | September 2025 | Allow | 28 | 0 | 0 | No | No |
| 18254319 | USE OF ZANAMIVIR IN PREPARATION OF DRUG FOR TREATING OR PREVENTING PREECLAMPSIA | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18305688 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | April 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18132677 | METHOD FOR PRODUCING PYRROLE COMPOUND | April 2023 | September 2024 | Allow | 18 | 0 | 1 | No | No |
| 18114584 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND TEHIR USES | February 2023 | October 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18043087 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUORO-1,3-BENZODIOXOLE DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18108053 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | February 2023 | June 2024 | Allow | 17 | 0 | 1 | No | No |
| 18097640 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | January 2023 | February 2025 | Allow | 25 | 1 | 1 | No | No |
| 18066677 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | December 2022 | October 2024 | Abandon | 22 | 0 | 1 | No | No |
| 18057742 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | November 2022 | November 2024 | Allow | 24 | 2 | 1 | No | No |
| 17989859 | CRYSTALLINE EPINEPHRINE MALONATE SALT | November 2022 | June 2024 | Allow | 19 | 1 | 0 | No | No |
| 17935949 | GABA COMPLEX COMPOSITION | September 2022 | November 2025 | Allow | 37 | 2 | 0 | No | No |
| 17905973 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | September 2022 | July 2024 | Allow | 22 | 0 | 1 | No | No |
| 17940585 | INSECT REPELLENT COMPOUNDS AND COMPOSITIONS, AND METHODS THEREOF | September 2022 | October 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17929931 | PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS | September 2022 | October 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17929285 | PHARMACEUTICAL COMPOSITIONS COMPRISING ONE OR MORE PYRONE COMPOUNDS, AND THEIR USE FOR TREATING INFLAMMATORY AND NEURODEGENERATIVE DISEASES | September 2022 | September 2024 | Allow | 25 | 2 | 1 | No | No |
| 17759710 | Method of Preventing or Treating Pancreatic Dysfunction or Diabetes by Upregulating Human Cathelicidin LL-37 to Inhibit Islet Amyloid Polypeptide (IAPP) Self-Assembly | July 2022 | November 2025 | Allow | 39 | 0 | 0 | No | No |
| 17788534 | CHEMICAL COMPOUNDS TARGETING THE EYE AND USE THEREOF IN THE TREATMENT OF EYE DISEASES | June 2022 | September 2024 | Allow | 27 | 0 | 0 | No | No |
| 17750560 | DNA PRIMASE AND GYRASE INHIBITORS | May 2022 | March 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17755946 | BIOTIN-CONTAINING MONOMERS AND ARTICLES FORMED THEREFROM | May 2022 | September 2025 | Allow | 40 | 0 | 0 | No | No |
| 17774843 | FUNCTIONALLY MODIFIED MAYTANSINOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF | May 2022 | October 2025 | Allow | 42 | 1 | 0 | No | No |
| 17730112 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | April 2022 | February 2024 | Allow | 22 | 2 | 0 | No | Yes |
| 17754837 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | April 2022 | January 2026 | Allow | 45 | 1 | 0 | No | No |
| 17704500 | SOLAR CELL DYES FOR COPPER REDOX BASED DYE SENSITIZED SOLAR CELLS AND COMBINATIONS THEREOF | March 2022 | January 2026 | Allow | 46 | 1 | 0 | No | No |
| 17639302 | METHODS OF SYNTHESIZING CANNABIELSOIN AND ANALOGS THEREOF | February 2022 | July 2024 | Allow | 28 | 0 | 0 | No | No |
| 17632909 | AGONISTS OF ROR GAMMAt | February 2022 | October 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17633151 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | February 2022 | October 2024 | Allow | 33 | 1 | 1 | No | No |
| 17632985 | MOLECULAR COMPLEXES | February 2022 | March 2026 | Abandon | 49 | 1 | 0 | No | No |
| 17627214 | COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND COMPOSITIONS AND USES THEREOF | January 2022 | November 2023 | Abandon | 22 | 2 | 1 | No | No |
| 17618878 | Compounds For Modulating FXR | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17596353 | IMPROVED METHODS FOR CONVERTING CANNABIDIOL INTO DELTA9-TETRAHYDROCANNABINOL UNDER PROTIC REACTION CONDITIONS | December 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17457733 | FUSED THIOPHENE COMPOUNDS | December 2021 | June 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17613910 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | November 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17608434 | COMPOUNDS AND METHODS FOR TREATING CANCER | November 2021 | January 2025 | Allow | 39 | 1 | 1 | No | No |
| 17608256 | SULFUR AND AMIDE TROPOLONE INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USES THEREFOR | November 2021 | December 2025 | Allow | 49 | 4 | 1 | No | No |
| 17605170 | MELOXICAM CO-CRYSTAL COMPOSITIONS | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17469773 | SELF-ASSEMBLED ACTIVE AGENTS | September 2021 | April 2024 | Allow | 31 | 3 | 1 | No | No |
| 17446807 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | September 2021 | May 2023 | Allow | 20 | 1 | 0 | No | No |
| 17310941 | PREPARATION OF MAYTANSINOL | September 2021 | October 2024 | Allow | 37 | 0 | 1 | No | No |
| 17370201 | COMPOUNDS FOR TREATMENT OF CANCER | July 2021 | June 2024 | Allow | 35 | 3 | 1 | No | No |
| 17359661 | SYNTHESIS METHOD FOR HALOFUGINONE AND HALOFUGINONE INTERMEDIATES | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17351350 | BUTHIONINE SULFOXIMINE AND A METALLODRUG FOR THE TREATMENT OF CANCER, HIV OR A RHEUMATIC DISEASE | June 2021 | July 2024 | Allow | 37 | 3 | 1 | No | No |
| 17283441 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | April 2021 | December 2024 | Allow | 44 | 1 | 1 | No | No |
| 17272346 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | February 2021 | July 2024 | Allow | 40 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHTERENGARTS, SAMANTHA L.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHTERENGARTS, SAMANTHA L works in Art Unit 1623 and has examined 586 patent applications in our dataset. With an allowance rate of 98.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 22 months.
Examiner SHTERENGARTS, SAMANTHA L's allowance rate of 98.3% places them in the 91% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHTERENGARTS, SAMANTHA L receive 1.17 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SHTERENGARTS, SAMANTHA L is 22 months. This places the examiner in the 88% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +1.8% benefit to allowance rate for applications examined by SHTERENGARTS, SAMANTHA L. This interview benefit is in the 21% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 39.9% of applications are subsequently allowed. This success rate is in the 90% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 72.9% of cases where such amendments are filed. This entry rate is in the 93% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 49.4% are granted (fully or in part). This grant rate is in the 45% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 21.5% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.